Sir,
We thank Dr Floriani and co-workers for their interest in our work and for their stimulating comments. It is important to highlight that so far in metastatic colorectal cancer patients, treatment with cetuximab or panitumumab is accomplished to block or to destroy metastatic cells, whereas the evaluation of molecular markers able to predict the efficacy of these therapies has been performed mostly on primary tumours. Historically, the choice of researchers to use primary tumours for molecular studies was made because biopsies of the metastatic lesions were not available in the majority of patients. As a consequence, it is reasonable to hypothesise that primary tumours and related distant metastatic lesions may show different molecular fingerprints that may affect the prediction of response to targeted therapies.
We agree with Floriani and co-workers that K-Ras is the only universally accepted determinant of resistance to EGFR-targeted drugs. However, recent pre-clinical (Di Nicolantonio et al, 2008; Jhawer et al, 2008) and clinical (Frattini et al, 2007; Di Nicolantonio et al, 2008; Sartore-Bianchi et al, 2009) data show that other members of the EGFR downstream pathways (e.g., BRAF, PTEN and PIK3CA) may have a predictive role in this context. We found a rationale for our studies as no previous works reported a simultaneous comparison of these markers in the same cohort of patients. To evaluate the discrepancies between primary tumour and paired distant metastatic lesions, we applied Cohen's kappa test, one of the most used and solid tests for this type of work. Our results are in line with the few data available in the literature on this topic and, although not statistically significant, the results suggest that differences between primary tumour and metastases may be clinically relevant for a given patient. We are therefore pleased that Floriani and co-workers after reading our work came to the same conclusions, namely that prospective studies on this important topic are extremely urgent.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705–5712
Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139–1145
Jhawer M, Goel S, Wilson AJ (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953–1961
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851–1857
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Frattini, M., Molinari, F., Saletti, P. et al. Reply: Do we need biopsies of metastases for colorectal cancer patients?. Br J Cancer 101, 376 (2009). https://doi.org/10.1038/sj.bjc.6605170
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605170